Mutations in the LNK gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJason Robert Gotlib, Garry P. Nolan, James L. Zehnder, Stephen Tracy Oh
Life of this patent
Estimating the term…
Abstract
Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
Claims3
A method of identifying a human subject as having or being predisposed to a hematolymphoid neoplasm or malignancy, comprising:
- (a) obtaining a sample derived from a subject, wherein the sample comprises blood cells and wherein the blood cells do not have a JAK2 V617F mutation;
- (b) determining the sequence of an LNK gene derived from the sample using PCR or sequencing;
- and
- (c) identifying the subject as having or being predisposed to a hematolymphoid neoplasm or malignancy based on the determination in step (b) that the LNK gene has an E208Q mutation or a mutation consisting of 603 607delGCGCT and 613C>G.
Dependencies are inferred from the claim text.